MK-6325

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C42H56N6O9S
Molecular Weight	820.994
Optical Activity	UNSPECIFIED
Defined Stereocenters	7 / 7
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

COC1=CC2=C(C=C1)N=C3CCCCC[C@@H]4CCC[C@H]4OC(=O)N[C@H]5CCCCC\C=C\[C@@H]6C[C@]6(NC(=O)[C@@H]7C[C@H](CN7C5=O)OC3=N2)C(=O)NS(=O)(=O)C8(C)CC8

InChI

InChIKey=BLFKRFGLQFYXDF-WAZRELCSSA-N

InChI=1S/C42H56N6O9S/c1-41(20-21-41)58(53,54)47-39(51)42-24-27(42)14-8-4-3-5-9-16-32-38(50)48-25-29(23-34(48)36(49)46-42)56-37-31(43-30-19-18-28(55-2)22-33(30)44-37)15-10-6-7-12-26-13-11-17-35(26)57-40(52)45-32/h8,14,18-19,22,26-27,29,32,34-35H,3-7,9-13,15-17,20-21,23-25H2,1-2H3,(H,45,52)(H,46,49)(H,47,51)/b14-8+/t26-,27-,29-,32+,34+,35-,42-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C42H56N6O9S
Molecular Weight	820.994
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	7 / 7
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description

MK-6325 is a potent HCV NS3/4A protease inhibitor patented by Merck Sharp & Dohme Corp for treating or preventing HCV infections. In 2011 MK-6325 was studied in phase I clinical trials but no further development reports were published.

Originator

Approval Year

PubMed

Show entries

Title	Date	PubMed
Synthesis of bis-macrocyclic HCV protease inhibitor MK-6325 via intramolecular sp²-sp³ Suzuki-Miyaura coupling and ring closing metathesis.	2015 Mar 20	25754231

Showing 1 to 1 of 1 entries

Previous1Next

Patents

Sample Use Guides

In Vivo Use Guide

Eight 100 mg capsules, orally, once per day for 7 days

Route of Administration: Oral

Substance Class	Chemical
Record UNII	59LD48P07K
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

MK 6325

Preferred Name

English

MK-6325

Common Name

English

7,19:18,21-DIMETHANO-19H-CYCLOPENTA(28,29)CYCLOPROPA(12,13)(1,20,3,14,17)DIOXATRIAZACYCLONONACOSINO(21,22-B)QUINOXALINE-15A(16H)-CARBOXAMIDE, 1,2,3,3A,5,6,7,8,9,10,11,12,14A,15,17,18,20,21,29,30,31,32,33,33A-TETRACOSAHYDRO-25-METHOXY-N-((1-METHYLCYCLOPRO

Systematic Name

English

Showing 1 to 3 of 3 entries

Previous1Next

Show entries

Code System

Code

Type

Description

CAS

1263814-52-3

PRIMARY

FDA UNII

59LD48P07K

PRIMARY

PUBCHEM

121596640

PRIMARY

DRUG BANK

DB15249

PRIMARY

Showing 1 to 4 of 4 entries

Previous1Next

Show entries

Related Record

Type

Details


					59LD48P07K

MK-6325

ACTIVE MOIETY

Comments:

Clinical Trial Summary: This is a 2 part study of the safety, pharmacokinetics and pharmacodynamics of MK-6325 in HCV-infected participants. Part I of the study will be for Genotype (GT) 1 HCV-infected participants who will be randomized to receive either MK-6325 or placebo. If the drug is shown to be safe and efficacious in Part I, Part II will enroll GT 3 HCV-infected participants who will be randomized to receive either MK-6325 or placebo.


					59LD48P07K

MK-6325

ACTIVE MOIETY

Comments:

Originator: Merck & Co; Class: Antiviral; Mechanism of Action: Undefined mechanism; Orphan Drug Status: No; On Fast track: No; Highest Development Phase: No development reported for Hepatitis C; Most Recent Events: 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C in Germany (PO, Capsule), 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C in Moldova (PO, Capsule), 30 Apr 2012 Merck completes a phase I trial in Hepatitis C in Germany & Moldova (NCT01329913)


					59LD48P07K

MK-6325

ACTIVE MOIETY

Comments:

Enzyme Inhibition Ki(nM): 1b=0.005+-0.002, 3a=0.263+-0.107, R155K=0.013+-0.005, A156T=0.418+-0.147, A156V=0.568+-0.209, D168Y=0.036+-0.014; gt1b EC50(nM): 10% FBS=1.1+-0.8, 50% NHS=10.5+-3.1; Rat PK AUC 04h: (uM h)=0.77, (liver) 4h (uM)=43 MK-6325 is slightly more potent, with IC50 values < 0.263 nm across genotypes, and most being < 0.1 nm.

Showing 1 to 3 of 3 entries

Previous1Next